List view / Grid view

Dr Michael Davidson

 

article

Taming cardiovascular risk: the promise of LDL cholesterol lowering therapeutics

In this exclusive interview, CEO of NewAmsterdam Pharma, Michael Davidson,…

15 February 2024 | By

In this exclusive interview, CEO of NewAmsterdam Pharma, Michael Davidson, offers insight into the low-density lipoprotein (LDL) cholesterol lowering therapeutic landscape and shares promising data from the company’s lead candidate, a cholesterol ester transfer protein (CETP) inhibitor.